Abivax Shares Drop 3.84% at Midday on Annual Results Day
Abivax shares fell 3.84% to €105.20 at midday this Monday, as the French biotech company released its annual results for 2025. The decline occurred during a volatile session on the CAC 40, marked by strong geopolitical tensions in the early morning followed by a rebound. Over the year, however, the stock still boasts an exceptional performance of nearly 1,450%.
Abivax Shares Decline Amid Annual Results Announcement
Abivax shares dropped 3.84% this Monday at midday, falling to €105.20 from €109.40 at last Friday's close. This decline coincides with the publication date of the 2025 annual results, a scheduled event in the company's financial calendar. Over the past seven days, however, the stock has shown a gain of 3.95%, while the quarterly performance remains negative at -8.84%. The CAC 40 is up by 0.61% at 7,712 points, after dropping more than 2% in the morning due to geopolitical tensions related to Iran before rebounding. In the pharmaceutical sector, Sanofi has marginally increased by 0.06% and UCB is up by 0.89%, highlighting a movement specific to Abivax rather than a sector-wide trend. The biotech, specializing in chronic inflammatory bowel diseases, had seen its share price increase more than fifteenfold over the year, driven by advancements in its drug candidate obefazimod. Today's session will be closely watched for the annual figures released, which could shed light on the company's financial trajectory.
Technical Analysis of Abivax Stock
From a technical analysis standpoint, Abivax's stock price remains above its 50-day moving average, set at €102.36, a level that serves as a benchmark for assessing medium-term momentum. As long as the stock stays above this threshold, the upward trend that started in recent weeks remains intact. The difference with the 200-day moving average (€75.79) also reflects the magnitude of the rally observed over the past year. The RSI, a relative strength indicator that measures the intensity of recent stock movements, is at 61, which is in a neutral to moderately bullish zone, away from the overbought thresholds (beyond 70) that would indicate an increased risk of a prolonged correction. On the technical levels side, the nearest resistance is at €112.40, while the identified support at €94.00 serves as a floor to watch in case of a downward acceleration. The monthly volatility, measured at 15.36%, remains significant for a stock of this size, characteristic of biotechs whose prices are closely linked to the progress of their clinical programs.
